Global websites

Global: English

Local websites

France: Français
Germany: Deutsch
Japan: 日本語
Netherlands: Nederlands
Spain: Español
United Kingdom: English
United States: English

Locations map

Press Releases

2013

November 3, 2013

arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B

September 18, 2013

arGEN-X reaches milestone in SIMPLE Antibody™ research and product development collaboration with Shire

September 16, 2013

arGEN-X initiates Phase Ib study of ARGX-111 in cancer

September 11, 2013

arGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7

August 5, 2013

arGEN-X grants license to its NHance™ antibody half-life extension technology

April 25, 2013

arGEN-X to Present at Upcoming Ninth Annual PEGS 2013

March 24, 2013

arGEN-X announces preclinical development of ARGX-112 for dermatology

January 6, 2013

arGEN-X initiates Phase Ib study of ARGX-110 in cancer

January 6, 2013

arGEN-X expands its therapeutic antibody alliance with Shire

2012

December 5, 2012

arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform

November 5, 2012

arGEN-X reveals the target and unique mechanism of action of its most advanced preclinical antibody at the PEGS Summit 2012

October 24, 2012

arGEN-X appoints Dr. David L. Lacey to its supervisory board